Scarica l'app Stockscreener
27.96
3.79%
1.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis - simplywall.st
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
The Bull Case For TG Therapeutics (TGTX) Could Change Following New Azer-cel Milestone In Progressive MS - Sahm
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz
TGTX (TG Therapeutics) Total Assets : $1,063.3 Mil (As of Dec. 2025) - GuruFocus
Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir
TG Therapeutics to present BRIUMVI data at neurology meeting By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky - MarketBeat
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - The Manila Times
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Yahoo Finance
HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - simplywall.st
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 - Finviz
TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives - Sahm
TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap - Sahm
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - The Globe and Mail
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
TG THERAPEUTICS, INC. SEC 10-K Report - TradingView
TG Therapeutics: "Strong Buy" On BRIUMVI's Massive Growth And Possible Expansion (TGTX) - Seeking Alpha
(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
TG Therapeutics Experiences Evaluation Revision Amidst Evolving Market Dynamics - Markets Mojo
TG Therapeutics Q4 Earnings Call Highlights - MarketBeat
Q1 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
TG Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript - The Globe and Mail
Earnings call transcript: TG Therapeutics Q4 2025 earnings miss EPS expectations - Investing.com
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates - Yahoo! Finance Canada
TG Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TG Therapeutics: Fourth Quarter Financial Highlights - Bitget
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):